Compile Data Set for Download or QSAR
maximum 50k data
Found 13 Enz. Inhib. hit(s) with all data for entry = 6150
TargetSteroid 17-alpha-hydroxylase/17,20 lyase(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM111999(US8623892, 1)
Affinity DataIC50:  180nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSteroid 17-alpha-hydroxylase/17,20 lyase(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112001(US8623892, 3)
Affinity DataIC50:  220nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSteroid 17-alpha-hydroxylase/17,20 lyase(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112002(US8623892, 4)
Affinity DataIC50:  510nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSteroid 17-alpha-hydroxylase/17,20 lyase(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112000(US8623892, 2)
Affinity DataIC50:  960nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112000(US8623892, 2)
Affinity DataIC50:  5.50E+3nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112001(US8623892, 3)
Affinity DataIC50:  1.20E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112001(US8623892, 3)
Affinity DataIC50:  1.90E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112001(US8623892, 3)
Affinity DataIC50:  2.30E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112000(US8623892, 2)
Affinity DataIC50:  2.30E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM111999(US8623892, 1)
Affinity DataIC50:  3.30E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM112000(US8623892, 2)
Affinity DataIC50:  3.30E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM111999(US8623892, 1)
Affinity DataIC50:  3.90E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM111999(US8623892, 1)
Affinity DataIC50:  5.70E+4nMAssay Description:In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target an...More data for this Ligand-Target Pair
In DepthDetails US Patent